Summary of Disc Medicine Conference Call Company Overview - **Company**: Disc Medicine - **Focus**: Hematology, specifically targeting pathways of red blood cell biology and iron metabolism - **Lead Programs**: Bidipertin for erythropoietin protoporphyria and DISCO-nine 74 for anemia of myelofibrosis [3][6][8] Industry Context - **Disease Focus**: Myelofibrosis, a type of blood cancer characterized by anemia, splenomegaly, and constitutional symptoms [16][22] - **Current Treatment Landscape**: - Four JAK inhibitors approved for myelofibrosis, primarily targeting spleen size reduction and symptom improvement [46][49] - No approved therapies specifically for anemia of myelofibrosis, leading to significant unmet medical needs [19][45] Key Points from the Call Myelofibrosis and Anemia - **Prevalence**: Approximately 25,000 patients in the U.S. diagnosed with myelofibrosis, with a five-year survival rate around 50% [26][27] - **Anemia Statistics**: - 40% of patients present with significant anemia at diagnosis, increasing to 60% within one year [36] - Nearly all patients will develop anemia over the disease course, with transfusion dependency rising from 25% at diagnosis to 45% within a year [36][37] - **Prognostic Importance**: Anemia is a significant prognostic factor, with lower hemoglobin levels correlating with worse survival outcomes [30][38] Current Treatment Limitations - **JAK Inhibitors**: While effective for managing symptoms, they often exacerbate anemia, leading to treatment discontinuation in many patients [60][61] - **Existing Treatments for Anemia**: Use of erythropoietin, steroids, and androgens, but these are not specifically approved for myelofibrosis-related anemia [49][50] Emerging Therapies - **DISCO-nine 74**: - A monoclonal antibody targeting hepcidin suppression to mobilize iron for red blood cell production [8][10] - Phase 1b data shows promise in treating anemia of myelofibrosis [14][19] - **Luspatercept and Elitracept**: - Both are in development as potential treatments for anemia, with luspatercept already approved for MDS [79][80] - Phase 3 trials for luspatercept are ongoing, focusing on patients requiring transfusions while on stable doses of JAK inhibitors [80] Market Opportunity - **Anemia of Myelofibrosis**: Significant market opportunity exists for effective treatments targeting anemia, given the high prevalence and unmet needs [19][45] - **Potential Impact of New Therapies**: New treatments could improve patient quality of life, reduce healthcare costs associated with transfusions, and address the underlying pathophysiology of anemia in myelofibrosis [40][41][44] Conclusion - The call emphasized the critical need for new therapies specifically targeting anemia in myelofibrosis, highlighting the potential of DISCO-nine 74 and other emerging treatments to fill this gap in the current treatment landscape [19][45][76]

Core Viewpoint - Disc Medicine, Inc. is hosting a virtual KOL investor event to discuss anemia of myelofibrosis (MF) and the treatment landscape, including clinical data and development plans for its investigational drug DISC-0974 [1][2] Group 1: Event Details - The virtual event is scheduled for May 9, 2025, at 1:00 PM ET / 10:00 AM PT [1] - Presentations will include insights from leading experts on myeloproliferative neoplasms (MPNs) and the unmet need for anemia-focused treatments [2] - A live webcast will be available on Disc's Investor Relations page, with a replay accessible for 90 days [3] Group 2: DISC-0974 Overview - DISC-0974 is a monoclonal antibody targeting hemojuvelin (HJV) to suppress hepcidin production and increase serum iron levels in patients with anemia of inflammation [4] - The drug was in-licensed from AbbVie in 2019 and has shown clinical proof-of-mechanism in previous trials [4] - Ongoing clinical trials include a Phase 2 trial in MF anemia and a Phase 1b/2a trial in chronic kidney disease patients [4] Group 3: Anemia of Myelofibrosis - Myelofibrosis affects an estimated 25,000 patients in the U.S., with over 80% presenting with anemia at diagnosis [6] - Hepcidin levels are approximately 12-fold elevated in MF patients, correlating with disease severity and the need for red blood cell transfusions [6] Group 4: Company Background - Disc Medicine is focused on developing novel treatments for serious hematologic diseases, targeting biological pathways related to red blood cell biology [7][8]